Title: Martin Dreyling - Innovator in Cancer Treatment
Introduction
Martin Dreyling is an accomplished inventor based in Planegg, Germany. He is currently associated with Lindis Biotech GmbH, where he focuses on developing innovative therapies for cancer treatment. Although he has not yet been granted any patents, his work in the field is noteworthy.
Latest Patent Applications
Dreyling's latest patent applications include significant advancements in cancer treatment. One application is titled "Subcutaneously Administered Bispecific Antibodies for Use in the Treatment of Cancer." This invention relates to the use of T cell redirecting, bispecific, particularly trifunctional, antibodies for treating cancer. The method involves administering the antibody via the subcutaneous route, which reduces the release of proinflammatory cytokines while suppressing inhibitory cytokines. This treatment can be combined with other anti-cancer drugs for enhanced efficacy.
Another application is "Combination Therapy of an Afucosylated CD20 Antibody with Fludarabine and/or Mitoxantrone." This invention focuses on the combination therapy of an afucosylated anti-CD20 antibody with fludarabine and/or mitoxantrone for treating cancer. It specifically targets CD20 expressing cancers using an afucosylated humanized B-Ly1 antibody in conjunction with these drugs.
Conclusion
Martin Dreyling is making significant contributions to cancer treatment through his innovative patent applications. His work at Lindis Biotech GmbH showcases his commitment to advancing medical science and improving patient outcomes.
Inventor’s Patent Attorneys refers to legal professionals with specialized expertise in representing inventors throughout the patent process. These attorneys assist inventors in navigating the complexities of patent law, including filing patent applications, conducting patent searches, and protecting intellectual property rights. They play a crucial role in helping inventors secure patents for their innovative creations.